Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL.

Antimicrob Agents Chemother. 2009 Jan;53(1):129-35. doi: 10.1128/AAC.00708-08. Epub 2008 Oct 13.

2.

In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.

Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL.

Antimicrob Agents Chemother. 2007 Nov;51(11):3988-4000. Epub 2007 Sep 10.

3.

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL.

Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8. Epub 2007 Aug 27.

4.

Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Louie A, Deziel MR, Liu W, Drusano GL.

Antimicrob Agents Chemother. 2007 Aug;51(8):2661-7. Epub 2007 May 21.

5.

Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL.

J Infect Dis. 2007 Jun 15;195(12):1818-27. Epub 2007 May 2.

PMID:
17492598
6.
7.

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A.

Antimicrob Agents Chemother. 2006 Nov;50(11):3695-700. Epub 2006 Sep 5.

8.

The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.

Drusano GL, Louie A, Deziel M, Gumbo T.

Clin Infect Dis. 2006 Feb 15;42(4):525-32. Epub 2006 Jan 3. Review.

PMID:
16421797
9.

Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.

Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL.

Antimicrob Agents Chemother. 2006 Jan;50(1):310-7.

10.

Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly M, Drusano GL.

Antimicrob Agents Chemother. 2005 Dec;49(12):5099-106.

11.

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL.

Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68.

12.
13.

Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.

Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL.

J Infect Dis. 2005 Aug 1;192(3):420-8. Epub 2005 Jul 5.

PMID:
15995955
14.

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL.

J Infect Dis. 2004 Nov 1;190(9):1642-51. Epub 2004 Sep 24. Erratum in: J Infect Dis. 2004 Dec 1;190(11):2059.

PMID:
15478070
15.

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL.

J Clin Invest. 2003 Jul;112(2):275-85.

16.

Myofibrillar protein structure and assembly during idiopathic dilated cardiomyopathy.

Levine RJ, Caulfield JB, Norton P, Chantler PD, Deziel MR, Slayter HS, Margossian SS.

Mol Cell Biochem. 1999 May;195(1-2):1-10.

PMID:
10395063
17.

Calcium regulation in the human myocardium affected by dilated cardiomyopathy: a structural basis for impaired Ca2+-sensitivity.

Margossian SS, Anderson PA, Chantler PD, Deziel M, Umeda PK, Patel H, Stafford WF, Norton P, Malhotra A, Yang F, Caulfield JB, Slayter HS.

Mol Cell Biochem. 1999 Apr;194(1-2):301-13.

PMID:
10391153
18.
20.

Selective effects of charge on G protein activation by FSH-receptor residues 551-555 and 650-653.

Grasso P, Deziel MR, Reichert LE Jr.

Pept Res. 1995 Sep-Oct;8(5):278-84.

PMID:
8589550
21.
22.

A decapeptide corresponding to the partial amino acid sequence of a high molecular weight human FSH receptor-binding inhibitor is a specific inhibitor of FSH binding.

Lee DW, Grasso P, Leng N, Izquierdo R, Crabb JW, Deziel MR, Reichert LE Jr.

Pept Res. 1995 May-Jun;8(3):171-7.

PMID:
7670232
23.

Retinoic acid inhibition of thyroxine binding to human transthyretin.

Smith TJ, Davis FB, Deziel MR, Davis PJ, Ramsden DB, Schoenl M.

Biochim Biophys Acta. 1994 Jan 5;1199(1):76-80.

PMID:
8280758
24.

Effects of aging, diet, and sex on plasma glucose, fructosamine, and lipid concentrations in barrier-raised Fischer 344 rats.

Van Liew JB, Davis PJ, Davis FB, Bernardis LL, Deziel MR, Marinucci LN, Kumar D.

J Gerontol. 1993 Sep;48(5):B184-90.

PMID:
8366257
25.

Purification of a high molecular weight follicle-stimulating hormone receptor-binding inhibitor from human follicular fluid.

Lee DW, Grasso P, Dattatreyamurty B, Deziel MR, Reichert LE Jr.

J Clin Endocrinol Metab. 1993 Jul;77(1):163-8.

PMID:
8325939
26.

Thyroid hormone stimulates release of calmodulin-enhancing activity from human erythrocyte membranes in vitro.

Lawrence WD, Deziel MR, Davis PJ, Schoenl M, Davis FB, Blas SD.

Clin Sci (Lond). 1993 Feb;84(2):217-23.

PMID:
8382586
27.

Hexose-specific inhibition in vitro of human red cell Ca(2+)-ATPase activity.

Deziel MR, Safeer RS, Blas SD, Davis FB, Davis PJ.

Biochim Biophys Acta. 1992 Sep 21;1110(1):119-22.

PMID:
1390832
28.

Effects of caloric restriction and aging on erythrocyte membrane Ca(2+)-ATPase activity in specific pathogen-free Fischer 344 rats.

Davis FB, Deziel MR, Van Liew JB, Davis PJ, Bernardis LL, Blas SD.

Metabolism. 1991 Aug;40(8):819-24.

PMID:
1650420
30.
31.

Interaction of amiodarone and its analogs with calmodulin.

Deziel MR, Davis PJ, Davis FB, Cody V, Galindo J Jr, Blas SD.

Arch Biochem Biophys. 1989 Nov 1;274(2):463-70.

PMID:
2552925
32.
33.

Further characterization and chemical purity assessment of the human erythrocyte glucose transporter preparation.

Rampal AL, Jung EK, Chin JJ, Deziel MR, Pinkofsky HB, Jung CY.

Biochim Biophys Acta. 1986 Jul 24;859(2):135-42.

PMID:
3730374
34.
35.
37.

Labelling of the human erythrocyte glucose transporter with 3H-labelled cytochalasin B occurs via protein photoactivation.

Deziel M, Pegg W, Mack E, Rothstein A, Klip A.

Biochim Biophys Acta. 1984 May 30;772(3):403-6.

PMID:
6539126
38.
39.

[Lysogeny in group A streptococci and evaluation of culture media for detection of temperate bacteriophages obtained from these microorganisms].

Figueiredo AM, Benchetrit LC, Skjold SS, Deziel M, Wannamaker LW.

Rev Inst Med Trop Sao Paulo. 1983 Jan-Feb;25(1):16-21. Portuguese. No abstract available.

PMID:
6348925
40.
41.

[Teaching patient with chronic bronchopulmonary diseases].

Bleau L, Deziel M, Dumont-Faria L, Gagnon RA, Gauthier M, Lachance S, Latendresse L, Ricard M.

Nurs Que. 1980 Nov-Dec;1(1):30-7. French. No abstract available.

PMID:
6921537
42.

Photodynamic action of bilirubin on liposomes and erythrocyte membranes.

Deziel MR, Girotti AW.

J Biol Chem. 1980 Sep 10;255(17):8192-8. No abstract available.

43.

Bilirubin-photosensitized lysis of resealed erythrocyte membranes.

Deziel MR, Girotti AW.

Photochem Photobiol. 1980 Jun;31(6):593-6. No abstract available.

PMID:
7394001
44.

Methylene blue-sensitized photooxidation of hemoglobin: evidence for cross-link formation.

Girotti AW, Lyman S, Deziel MR.

Photochem Photobiol. 1979 Jun;29(6):1119-25. No abstract available.

PMID:
504349

Supplemental Content

Loading ...
Support Center